50.00 0.00 (0.00%)
After hours: 4:32PM EDT
|Bid||49.26 x 2200|
|Ask||51.33 x 28000|
|Day's range||49.42 - 50.21|
|52-week range||37.47 - 52.19|
|Beta (3Y monthly)||0.93|
|PE ratio (TTM)||N/A|
|Earnings date||5 Nov. 2019 - 11 Nov. 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||53.09|
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Hologic's (HOLX) strong top-line growth in Q3 is led by a solid year-over-year rise in core businesses like Breast Health and Molecular Diagnostics.
Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.
ResMed (RMD) achieves double-digit global revenue growth in the fourth quarter, led by strong sales at Software-as-a-Service businesses as well as of new mask products and devices.
While rising acquisitions and a favorable mix contribute to LabCorp's (LH) Diagnostics business, the disposition of certain businesses and the implementation of PAMA dented the company's growth in Q2.
Higher revenues, growth in APAC and raised 2019 EPS outlook benefit Baxter's (BAX) Q2 earnings. However, weak performance at Clinical Nutrition and margin contraction remains a woe.
Cerner (CERN) Q2 results benefit from higher revenues, gains in Licensed software, Professional and Managed services units, and gross margin expansion.
Neogen's (NEOG) strong international business and solid performance by core Food Safety segment resulted in year-over-year revenue growth.